An FDA Approved Drug Have Been Identified For Controlling Triple Negative Cancer

Triple negative cancer is one of the most deadly diseases experienced word wide. Research has shown that 1 in every 6 women diagnosed with breast cancer have triple negative cancer. This is due to the aggression with which the tumor grows and sometime is detected when it is out of control.

 A study conducted and published in the journal of cancer cell by Timmerman, an investigator at the centre for cancer, revealed that FAD approved drug can be used to prevent the movement of protein responsible for maintaining the development of the tumor. Triple negative cancer has been difficult to treat due to their inability to make their own receptors that can be a target to the drugs. However, this study found out that the growth of its cell can be slowed with application of the drug. While sulfasalazine itself would not be appropriate for treating cancer, it could serve as a "lead compound" that could be used to develop drugs that specifically target xCT on tumor cells. Timmerman said when reporting how his findings would be adopted.